CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
NRG-GY022 | NRG | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
NSABP-B-35 | NSABP | A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy | Adult CIRB - Late Phase Emphasis | Completed |
CALGB-40101 | CALGB | Cyclophosphamide and Doxorubicin (CA X 4 Cycles) Versus Paclitaxel (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study | Adult CIRB - Late Phase Emphasis | Completed |
EA8191 | ECOG-ACRIN | Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence | Adult CIRB - Late Phase Emphasis | Available to Open |
RTOG-1010 | RTOG | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma | Adult CIRB - Late Phase Emphasis | Completed |
E2810 | ECOG | Randomized; Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
S1418 | SWOG | A Randomized; Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-BN003 | NRG | Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma | Adult CIRB - Late Phase Emphasis | Available to Open |
E4599 | ECOG | Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC | Adult CIRB - Late Phase Emphasis | Completed |
GOG-0241 | GOG | A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) | Adult CIRB - Late Phase Emphasis | Completed |